Johnson & Johnson
NYSE: JNJ
$160.88
-$2.79 (-1.7%)
Closing Price on October 25, 2024
JNJ Articles
Earnings season is just kicking off for the third quarter with markets pushing all-time highs. Seven Dow stocks reporting this week, and nearly half of them are reporting on Tuesday.
Published:
Last Updated:
24/7 Wall St. has put together a preview of GE, Verizon and other the Dow Jones Industrial Average companies scheduled to report their quarterly results this week.
Published:
Last Updated:
Walmart, Johnson & Johnson, McDonald's, and Visa pushed the DJIA higher on Wednesday.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Wednesday include AbbVie, Gilead, Johnson & Johnson, Potash, Schlumberger, Visa and Walmart.
Published:
Last Updated:
These five new additions to Deutsche Bank’s Conviction List all make good sense for growth portfolios now.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Monday include Ctrip.com, Goldman Sachs, Johnson & Johnson, Medtronic, Morgan Stanley, Yelp and Yum China.
Published:
Last Updated:
U.S. pharmaceutical and biotech stocks may have considerable upside if Credit Suisse's views come to pass. But this part of the market has not come without controversy in the past year and a half.
Published:
Last Updated:
24/7 Wall St. has collected several catalysts that are coming up in October for biotech and pharmaceutical companies.
Published:
The top analyst upgrades, downgrades and other research calls from Monday include Albermarle, Blue Apron, Box, Dish Network, GM, Transocean and Under Armour.
Published:
Last Updated:
Apple, P&G, Johnson & Johnson, and Verizon led the DJIA lower on Thursday.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Wednesday include Biogen, Electronic Arts, Gap, Intuit, Johnson & Johnson, 3M, Intercept Pharmaceutical and AutoZone.
Published:
Last Updated:
Although the markets were mixed on Thursday, major drug manufacturers proved to be one of the more positive segments on the day.
Published:
Last Updated:
According to Merrill Lynch, the health care sector should act as a good hedge against volatility. Even biotech was shown to offer growth at a reasonable price.
Published:
Last Updated:
Achillion Pharmaceuticals saw its shares slump early on Monday after the firm announced that its hepatitis C license and collaboration agreement with Janssen had been terminated.
Published:
Last Updated:
Johnson & Johnson, Cisco Systems, Disney, and Caterpillar led the DJIA downward on Wednesday.
Published:
Last Updated: